The pineal hormone melatonin has been reported to protect tissue from oxidative damage. This study was designed to determine whether melatonin could prevent cell events leading to tissue injury and renal dysfunction after ischemia/reperfusion (I/R). Using an in vivo rat model of I/R, we show a significant increase in kidney malondialdehyde concentrations, reflecting lipid peroxidation, and cell apoptosis measured by TUNEL staining. This apoptotic cell death was associated with an increase in the activity of the proapoptotic factor caspase-3, determined by fluorometric protease activity assay. Histomorphological analysis of ischemic kidneys revealed that the most extensive tubular necrosis occurred at 24 and 48 h after reperfusion, which correlated with peak elevations in blood urea nitrogen and creatinine. Rat pretreatment with melatonin prevented lipid peroxidation, cell apoptosis, and necrosis and blocked caspase-3 activity. The prevention of tissue injury was associated with the improvement of renal function as shown by the decrease in blood urea nitrogen and creatinine concentrations. The demonstration that melatonin prevents postreperfusion apoptotic and necrotic cell death and improves renal function suggests that melatonin may represent a novel therapeutic approach for prevention of I/R injury.
A cute renal failure induced by ischemia/reperfusion (I/R) injury remains a major cause of morbidity and mortality among patients in the intensive care unit (1) . Indeed, this common clinical entity occurs during cardiopulmonary bypass (2) , kidney transplantation (3), aortic bypass surgery (4), accidental trauma (5), sepsis (6) , hydronephrosis (7) , and elective urological operations (8) . Although the exact mechanisms involved in the pathogenesis of acute renal failure have not been fully elucidated, it is generally believed that reactive oxygen species (ROS) are key mediators of the I/R-induced damage to the kidney. The excessive formation of ROS causes lipid peroxidation of cell membranes (9, 10) , protein and enzyme oxidation (11, 12) , and some irreversible DNA changes (13, 14) , leading to cell death in the form of necrosis or apoptosis.
Recent evidence suggests that apoptosis is the primary mode of cell death during renal I/R (15) . Apoptosis is a complex process involving a variety of different signaling pathways and results in a multitude of changes in the dying cell. Many of the events occurring during apoptosis are mediated by a family of cysteine proteases termed caspases (16) . Caspases participate in two distinct signaling pathways: activation of proinflammatory cytokines and promotion of apoptotic cell death (17) . Among the identified caspases, caspase-3 has been recognized as a key mediator of apoptotic death.
One of the approaches to limiting apoptotic cell death and caspase activation in response to I/R injury may be antioxidant therapy. Indeed, some antioxidants such as superoxide dismutase, vitamine E, glutathione, and catalase have shown protective properties against ischemia-induced tissue damage (18) (19) (20) (21) (22) . Melatonin is a pineal hormone with multiple functions, including the regulation of circadian and seasonal rhythms (23) , sleep (24) , and the immune system (25) . Many of the melatonin effects are mediated by specific high-affinity receptors (MT 1 , MT 2 ) localized on plasma membrane and coupled to G binding protein (26, 27) . Moreover, another melatonin binding site MT 3 with a 10-nM range affinity for melatonin has been recently purified in hamster and identified as the human homolog of the cytoplasmic quinone reductase (28) . It has also been shown that melatonin can be effective in preventing oxidative damage (29) . However, the cell mechanisms involved in melatonin's protective effects are still unclear, although the hypothesis that melatonin is a potent free-radical scavenger has been more often put forward. This study was designed to determine whether melatonin could prevent cell events leading to tissue injury and renal dysfunction after I/R.
MATERIALS AND METHODS
Melatonin was purchased from Sigma (Paris, France). HBSS medium was from Gibco-BRL (Eragny, France), polyvinylidene difluoride (PVDF) membrane from NEN Life Science Products (Boston, MA), anti-active mitogen-activated protein kinase (MAPK) polyclonal antibody from Promega (Madison, WI), Kit ECL detector reagents from Amersham (Buckinghamshire, UK), anti-rabbit polyclonal IgG ERK2 from Santa Cruz Biotechnology (Santa Cruz, CA), Bio-Rad DC protein assay reagents were from Bio-Rad Laboratories (Ivry-sur-Seine, France). Other chemicals were purchased from Sigma (St. Louis, MO).
Animals
All animal experiments were performed according to the principles of Laboratory Animal Care formulated by the National Society for Medical Research and the Guide for the Care and Use of Laboratory Animals (National Institutes of Health publication 86-23, revised 1989, authorization 00577, 1989, Paris, France).
Surgery and experimental protocols
Male Sprague-Dawley rats weighing 200-250 g (Harlan ZI Du Malcourlet, France) were housed individually in standard laboratory cages with ad libitum access to food and water. The rats were anesthesized with sodium pentobarbital (60 mg/kg, i.p.). In protocol 1, rats were subjected to unilateral ischemia by clamping of the right renal artery for 45 min, using a nontraumatic vascular clip. Sham-operated animals were subjected to the same surgical procedure without clamping the renal artery. Both kidneys were removed after 5 min (lipid peroxidation measurements) and 6 h of reperfusion (apoptosis and caspase-3 assays) for further analysis. These time points were chosen on the basis of our previous results (30) showing that unilateral renal ischemia induces lipid peroxidation in the first 5-15 min of reperfusion and maximal tubular apoptosis after 6 h of reperfusion.
In the unilateral model of renal ischemia, impairment of renal function may be compensated by intact contralateral kidney (31) . Therefore, to examine whether melatonin would improve the renal function after I/R, rats in protocol 2 were subjected to bilateral ischemia by clamping of both renal arteries for 45 min followed by reperfusion. After surgery, the animals were returned to the cages, where they had free access to food and water. The rats were killed at 24 h and 48 h of reperfusion, and plasma was collected from abdominal aorta at the time of death for measurement of creatinine and blood urea nitrogen (BUN). These time points were chosen on the basis of previous studies demonstrating that changes in creatinine and BUN occurred after 24 h and 48 h of reperfusion (32, 33) . In addition to biochemical assessment of kidney function, removed kidney tissues were fixed in Dubosc solution and were paraffin embedded for histological examination.
Animals in protocol 1 and protocol 2 were divided into four experimental groups: rats subjected to the surgical procedure without ischemia and treated with vehicle (S, n=4-6); rats subjected to the surgical procedure without schemia and treated with melatonin (M, n=4-6); rats subjected to ischemia and treated with vehicle (I/R, n=4-6); and rats subjected to ischemia and treated with melatonin (M+I/R, n=4-6).
Melatonin (Servier, France) was dissolved in polyethylene glycol 300/70% ethanol/H 2 O (40/10/50, vol/vol) and administered i.v. in a volume of 100 µl/100 g of body weight 15 min before ischemia. The dose of melatonin was based on the pharmacokinetic study of exogenous melatonin in animal models (34) .
Determination of malondialdehyde
Malondialdehyde (MDA) is an end product of peroxidation of cell membrane lipids caused by oxygen-derived free radicals. It was assayed in renal tissue from the level of chromogen obtained from the reaction of MDA with 2-thiobarbituric acid according to Aruoma et al. (35) , with some modifications. The kidneys obtained after 5 min of reperfusion were placed in 50 mM Tris-HCl (pH 7.4) containing 180 mM KCl and 10 mM EDTA in a total volume of 2 ml and homogenized. In brief, 20 µl homogenate were added to 980 µl water, 100 µl HCl (0.5 M), and 1 ml 0.8% thiobarbituric acid. This solution was heated to 95°C for 20 min. After addition of 2 ml of butanol-1, the mixture was centrifuged at 2000 rpm for 10 min at 4°C. The absorbance of the upper layer was read at 548 nm (Spectrofluo JY3 D, Jobin Yvon, Paris, France). MDA bisdimethyl acetal (Sigma) was used as the external standard. Results are expressed as nanomoles MDA per milligram protein.
Evaluation of apoptosis
Cell apoptosis was evaluated after 6 h of reperfusion. Using Dubosc-fixed and paraffinembedded sections, DNA fragmentation was visualized in situ on fixed tissues by terminal transferase-mediated dUTP nick-end labeling (TUNEL) staining (apoptosis detection kit, Promega). In brief, after they were rinsed, the deparaffinized sections were incubated in a 20 µg/ml proteinase K solution to permeabilize the tissues, rinsed, and fixed in 4% paraformaldehyde. The sections were incubated with 1 µl of terminal deoxynucleotidyl transferase (25 U/µl) and fluorescein-12-dUTP in equilibration buffer (25 mM Tris-HCl, pH 6.6; 200 mM potassium cacodylate, pH 6.6, 2.5 mM cobalt chloride, 0.25 mg/ml BSA, 0.2 mM DTT) for 1 h at 37°C. Then after rinsing four times in salt sodium citrate and phosphate-buffered saline, the slides were immersed in 40 ml propidium iodide solution (1µg/µl) for 15 min. The positive control was treated with DNase I (1 µg/µl) before being processed with the TUNEL procedure. To confirm the occurrence of apoptosis, the characteristic morphologic changes, including cell shrinkage and nuclear condensation, were detected by light microscopy.
Detection of caspase-3 activity
After 6 h of reperfusion, the renal activity of caspase-3 was determined by use of a fluorescent substrate as described previously (36) . Ac-Asp-Glu-Val-Asp-AMC (Ac-DEVD-AMC; Bachem) was used as a susceptible fluorescent substrate for caspase-3 (37) . In brief, the frozen kidney cortices were homogenized with 10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES, pH 7.4), containing 0.5% 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS), 42 mM KCl, 5 mM MgCl 2 , 1 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF), 2 µg/ml leupeptin, and 1 µg/ml pepstatin A. The homogenate was then centrifuged at 10,000g for 10 min. Caspase-3 activity was determined in supernatant by fluorometric assay, using the substrate Ac-DEVD-AMC. Supernatant (containing 250 µg total protein) was incubated with 40 µM of the caspase-3 substrate Ac-DEVD-AMC for 60 min at 37°C. At the end of incubation, substrate cleavage was monitored fluorometrically using a spectrophotometer (Spectrofluo JY3 D, Jobin Yvon) with an excitation wavelength of 380 nm and an emission wavelength of 460 nm. Data are expressed as arbitrary units per milligrams of proteins. One unit of enzyme activity is defined as the amount of enzyme required to liberate 40 µM of Ac-DEVD-AMC. Homogenate protein was measured by the Bradford method, as described in the Bio-Rad protein assay kit.
Renal function
Creatinine and blood urea nitrogen (BUN) were measured using a Vitros 950 Autoanalyzer (Clinical Diagnostics, Raritan, NJ).
Histological examination
Dubosc-fixed and paraffin-embedded kidney specimens were sectioned at 4 µm and stained using hematoxylin-eosin. Histological changes were evaluated by measuring tissue necrosis graded on a 0-5 scale in relation to the extent of kidney damage: 0=none; 1=<10%; 2=10-25%; 3=25-50%; 4=50-75%; 5=>75%. Tubular necrosis was assessed at 24 and 48 h after I/R.
Statistical analysis
The data are presented as means ±SE. Statistical analysis was performed using one-way ANOVA, followed by Newman-Keuls multiple comparisons. P<0.05 was considered statistically significant.
RESULTS

Effect of melatonin on lipid peroxidation induced by I/R
To determine whether melatonin attenuates oxidative stress induced by I/R, we measured the kidney levels of a marker of lipid peroxidation, MDA, in rats subjected to unilateral ischemia or to sham surgery. After 5 min of reperfusion, renal content of MDA was increased in vehicletreated ischemic rats compared with sham-operated animals (Fig. 1) . Melatonin treatment prevented postischemic MDA increase (Fig. 1) .
Effect of melatonin on cell apoptosis
Apoptosis was evaluated by detection of fragmented chromosomal DNA by TUNEL assay as shown in Figure 2 . The kidneys from rats in the vehicle-treated ischemic group showed extensive TUNEL-positive staining at 6 h of reperfusion, predominantly in the outer medulla ( Fig. 2A and  2B ). In contrast, kidneys from melatonin-treated rats were similar to those observed in shamoperated rats ( Fig. 2A and 2B ).
Effects of melatonin on caspase activity
To determine whether caspase activation plays a role in cell apoptosis observed at 6 h of reperfusion, we next measured the activity of caspase-3, a key mediator of apoptotic death. As shown in Figure 3 , caspase-3 activity was significantly increased in the vehicle-treated ischemic group at 6 h of reperfusion compared with the sham-operated groups. Pretreatment with melatonin fully inhibited the caspase-3 activation induced by I/R (Fig. 3) .
Effects of melatonin on renal function
To evaluate the effect of melatonin on recovery of renal function, experiments were performed in the bilateral model of renal I/R. Kidney function was evaluated by determining creatinine and BUN levels at 24 h and 48 h after reperfusion in animals subjected to sham surgery or to I/R. Ischemia, followed by reperfusion, produced significant increases in plasma concentrations of creatinine and BUN (Fig. 4) . However, administration of melatonin 15 min before ischemia significantly decreased creatinine and BUN concentrations after 24 h and 48 h of reperfusion, suggesting improved renal function.
Effects of melatonin on tubular necrosis after I/R
In addition to making a biochemical assessment of kidney function, we evaluated histomorphological alterations induced by bilateral renal ischemia at 24 h and 48 h of reperfusion. Histological sections of kidneys from vehicle-treated ischemic rats showed extensive tubular necrosis, mainly located at the proximal tubules after 24 h and 48 h of reperfusion ( Fig. 5 and Table 1 ). The histology of ischemic kidneys from rats pretreated with melatonin 15 min before ischemia was normal and indistinguishable from sham-operated animals ( Fig. 5 and Table 1 ). Treatment with melatonin in sham animals did not produce any detectable histological abnormalities.
DISCUSSION
In the present study, we demonstrate that melatonin inhibits caspase-3 activation and prevents postreperfusion apoptotic and necrotic cell death in the kidney. Furthermore, we have shown that melatonin reduces postreperfusion oxidative stress and improves the recovery of renal function. These results suggest that melatonin may represent a novel therapeutic approach for prevention of I/R injury.
Renal tubule cell apoptosis has been consistently observed after I/R in in vivo and in vitro models of renal injury (38, 39) and may represent a direct mechanism by which tubule cells are damaged. Prevention of cell apoptosis has been demonstrated to reduce ischemic damage in many organ systems (40) (41) (42) . An essential component of the apoptotic transduction pathway triggered by I/R is the intracellular generation of ROS. Melatonin has been found to protect cells from oxidative stress induced by a variety of free radical-generating agents and processes (43) (44) (45) . In fact, melatonin displays the antioxidant properties and plays a critical role in preserving the functional integrity of membrane lipids (46) . In the present study, we have demonstrated that postreperfusion lipid peroxidation is prevented by melatonin treatment, showing that melatonin reduces postreperfusion oxidative stress. In addition, we have also shown that melatonin reduces ischemia-induced cell apoptosis, suggesting that melatonin may act through apoptotic transduction pathways. Similar results were reported by Nava et al. (47) , who also found an antiapoptotic effect of melatonin in the course of nephrotoxic acute renal failure induced by HgCl 2 .
Several independent pathways have been implicated in the control of apoptotic death. Recent reports have indicated the importance of caspase families of proteins for apoptotic death. A member of this family, caspase-3, has been shown to be a major execution caspase that acts downstream in the apoptosis pathway and is involved in cleaving important substrates such as inhibitor of caspase-activated Dnase (48) . The investigation of caspase-3-deficient mice suggested that this enzyme, in particular, might be an appropriate target for therapeutic intervention in diseases that result from apoptosis (49) . The present study provides evidence that melatonin prevents the activation of the proapoptotic factor caspase-3 after postischemic injury. The fact that pretreatment of rats with melatonin prevents caspase-3-dependent cell apoptosis suggests that the mechanisms of melatonin's action may involve a caspase signaling cascade. There is some evidence suggesting that melatonin may act through signal transduction pathways to influence cellular activity. Melatonin receptors have been shown to inhibit several signal transduction cascades, including formation of cAMP, mobilization of calcium, release of arachidonic acid, and synthesis of diacylglycerol (50) (51) (52) (53) . It has also been shown that melatonin receptors may activate the MAPK cascade (54, 55) . Thus, the effects of melatonin are clearly not limited to its hypothetical direct free radical-scavenging ability and suggest that melatonin may signal through a variety of regulated pathways. However, it is unclear whether activation of melatonin receptors may participate in the prevention of postreperfusion renal injury by melatonin.
Although melatonin has been widely used in humans in the treatment of sleep disorders, we demonstrated that pretreatment with melatonin protects against the development of acute tubular necrosis and improves renal function after postreperfusion injury. Our findings imply that melatonin may be effective in protecting against oxidative stress-induced cell death. It is possible that prevention of necrotic cell death by melatonin confers a protective effect on overall tubular integrity and nephron function.
In conclusion, we report a novel finding regarding the protective effect of melatonin against renal ischemic injury in vivo. These results emphasize the importance of caspase signaling pathways to the protective effects of melatonin and represent a first step toward the characterization of the cellular and molecular mechanisms by which melatonin prevents I/R injury. The demonstration that melatonin pretreatment prevents caspase-3-dependent cell apoptosis and renal dysfunction after I/R may provide new therapeutic implications in the treatment of kidney diseases, which are characterized by apoptotic and necrotic cell death. a lipid peroxidation product was measured by the thiobarbituric acid assay in renal cortex homogenate 5 min after reperfusion. Sham-operated and ischemic groups of rats were treated with vehicle or melatonin (5 mg/kg, i.v.) 15 min before 45 min of unilateral ischemia. Data are expressed as the mean ±SE from four separate experiments. * P<0.01 vs. sham group. S, sham-operated rats treated with vehicle; M, sham-operated rats treated with melatonin; I/R, rats subjected to ischemia followed by reperfusion; M+I/R, rats treated with melatonin before ischemia followed by reperfusion. .001 vs. ischemic group. S, sham-operated rats treated with vehicle; M, sham-operated rats treated with melatonin; I/R, rats subjected to ischemia followed by reperfusion; M+I/R, rats treated with melatonin before ischemia followed by reperfusion. Caspase-3 activity was measured in supernatant by the fluorometric assay, using substrate Ac-Asp-Glu-Val-Asp-AMC (Ac-DEVD-AMC) in vehicle-treated and melatonin-treated rats subjected to unilateral ischemia for 45 min or to sham operation. Rats were killed at 6 h after reperfusion. One unit of enzyme activity is defined as the amount of enzyme required to liberate 40 µM of Ac-DEVD-AMC for 60 min at 37°C. Data are expressed as the mean ±SE from six independent experiments. * P<0.01 vs. sham group. S, sham-operated rats treated with vehicle; M, sham-operated rats treated with melatonin; I/R, rats subjected to ischemia followed by reperfusion; M+I/R, rats treated with melatonin before ischemia followed by reperfusion. § P<0.01 vs. I/R group. S, sham-operated rats treated with vehicle; M, sham-operated rats treated with melatonin; I/R, rats subjected to ischemia followed by reperfusion; M+I/R, rats treated with melatonin before ischemia followed by reperfusion. 
